GSK · Pharma and healthcare · one day
GSK (GSK): news on Thursday 5 November 2026
News from the 24 hours to Thursday morning, 5 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Most coverage was about HP naming GSK's former chief as its CEO, which says little about GSK itself. GSK-specific news leaned positive, led by Health Canada's approval of its hepatitis B therapy, maintained guidance and growth in specialty medicines, though vaccines were weaker and one report noted a share price dip.
What drove it
- Health Canada hepatitis B approval
- guidance and dividend
- specialty medicines growth
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Fri 30 Oct | −3.7 | 21 |
| Sat 31 Oct | +4.0 | 12 |
| Mon 2 Nov | +8.0 | 3 |
| Tue 3 Nov | +2.7 | 6 |
| Wed 4 Nov | +5.0 | 14 |
| Thu 5 Nov | +5.0 | 11 |
6 stories · 11 headlines · strongest first
Pharma and healthcare on 5 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| GSK share price moves +1.04 headlines today · Pieces report differing GSK share price moves and valuation views. | ||
| +3.3 | Shares rose five percent, though valuation looks stretched. | |
| +2.5 | Modest share gain on technical momentum. | |
| −2.5 | Share price falling. | |
| +0.8 | Generic stock overview, little substance. | |
| GSK Q3 growth led by specialty medicines +3.63 headlines today · Pieces report specialty medicines driving Q3 growth while vaccines slipped, with guidance and dividend reaffirmed. | ||
| +5.8 | Guidance maintained and dividend paid; valuation looks undervalued. | |
| +2.5 | Specialty drugs driving growth, offset by weaker vaccines. | |
| +2.5 | Specialty drugs driving growth, offset by weaker vaccines. | |
| Hibsago approved in Canada; priority review for bepirovirsen +10.01 headline today · 3 in all, since 4 November · Health Canada approved GSK's Hibsago for chronic hepatitis B. | ||
| +10.0 | Canadian approval of a first-of-kind hepatitis B therapy. | |
| Brokers split on GSK, cancer pipeline in focus +2.51 headline today · A piece discusses differing broker views and GSK's cancer pipeline. | ||
| +2.5 | Mixed broker views but cancer pipeline seen as promising. | |
| Alamar Biosciences and GSK proteomics study +4.41 headline today · 8 in all, since 4 November · Alamar signed a deal to analyse 60,000 serum samples for GSK. | ||
| +2.5 | GSK signs sample analysis agreement with a diagnostics firm. | |
| GSK brand management tips +1.71 headline today · A piece offers tips on keeping mature brands fresh. | ||
| +1.7 | GSK offering brand management insights, mildly positive profile. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.